HALOZYME THERAPEUTICS INC

FORM 5

(Annual Statement of Changes in Beneficial Ownership)

Filed 2/8/2005 For Period Ending 12/31/2004

Address 11588 SORRENTO VALLEY ROAD SUITE 17

SAN DIEGO, California 92121

Telephone (858) 794-8889

CIK 0001159036

Fiscal Year 12/31



FORM 5

[] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
[] Form 3 Holdings Reported
[] Form 4 Transactions

Reported

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0362 Expires: January 31, 2005 Estimated average burden hours per response... 1.0

ANNUAL STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(f) of the Investment Company Act of 1940

1. Name and Address of Reporting Person *									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
LIM JONAT	HAN E				ALOZYN C [HTI]	ИE	THER	APEUT	ICS	X Dire	ctor		10%	Owner
(Last)	(First)	(Mide	ile)	3. S	Statement for M/DD/YY	ΥY)		Ended	X Office below) President	cer (give title	e below)	Othe	er (specify
C/O HALOZ	YME					1	12/31/20	04		President	, CEO			
THERAPEU'	TICS, I	NC., 15	88											
SORRENTO 17	VALLI	EY RD.,	SUIT	E										
	(Street)				f Amendme	ent,	, Date Ori	ginal File	d	6. Individo		nt/Group l	Filing (Che	eck
SAN DIEGO.	CA 92	121												
(City)	(State)	(Zip)										Reporting Pethan One Rep		on
		Table I			1					Beneficially			T.	la v
1.Title of Security (Instr. 3)				2. Trans Date	. 2A. Deemed Execution Date, if any	Coc	de Astr. 8)	Acquired (A) Disposed of (A) Instr. 3, 4 and Or Amount (D)	or Follo	mount of Securit owing Reported 7 r. 3 and 4)			6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Table II - D) Perivative	Securition	es Acqui	red, D	isposed of	f, 01	r Benefici securitie		ed (<i>e.g.</i>	, puts, calls,	warrant	ts, options	s, convert	tible
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	nversion Date Deemed Execution Date, if any Possible of Possible of Possible Office of Possible Office Offi	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)				Form of Derivative Security: Direct (D)	11. Nature of Indirect Beneficial Ownership (Instr. 4)						
					(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Issuer's Fiscal Year (Instr. 4)	or Indirect (I) (Instr. 4)	
Options to Purchase Common Stock	\$2.05	10/13/2004		A	250000		2/1/2007 (1)	10/31/2014	Common Stock	250000	\$2.05	250000	D	
Options to Purchase Common Stock	\$2.02	12/8/2004		A	53422		12/8/2004 (2)	12/8/2014	Common Stock	53422	\$2.02	53422	D	

Explanation of Responses:

- (1) Options vest over a period of 50 months, with 1/20 vesting on February 1, 2007 and monthly thereafter until fully vested, contingent upon continued employment with Issuer.
- Options vest over a period of 48 months, with 50% of options vesting on date of grant and monthly thereafter until fully vested, contingent upon continued employment with Issuer.

Reporting Owners

	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
LIM JONATHAN E C/O HALOZYME THERAPEUTICS, INC. 1588 SORRENTO VALLEY RD., SUITE 17 SAN DIEGO, CA 92121	X		President, CEO				

Signatures
/s/ Jonathan E.
Lim

2/8/2005

Date

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

End of Filing



© 2005 | EDGAR Online, Inc.